BPC October 04 update

Sarepta SRPT shares rise on latest Duchenne muscular dystrophy data

Price and Volume Movers

DBV Technologies(Nasdaq: DBVT) announced the FDA has accepted for review the Biologics License Application (BLA) for Viaskin Peanut for the treatment of peanut allergy in children ages 4 to 11 years. The PDUFA date provided is August 5, 2020.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares closed up 9% to $88.25 on news of nine-month data from three Limb-girdle muscular dystrophy Type 2E (LGMD2E) patients who received SRP-9003. Improvements in functional outcomes were observed for all three participants.

Arbutus Biopharma Corporation (Nasdaq: ABUS) shares closed down 29% to $1.02 following news released Thursday that it will discontinue the development of AB-506 for the treatment of chronic hepatitis B. The decision follows two cases of acute hepatitis in a Phase 1a clinical trial in healthy volunteers.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume


Zosano Pharma Corporation (ZSAN): $1.96; +26%.

EyePoint Pharmaceuticals, Inc. (EYPT): $2.07; +18%.

Allena Pharmaceuticals, Inc. (ALNA): $4.00; +15%.

Eyenovia, Inc. (EYEN): $3.67; +11%.

Adamas Pharmaceuticals, Inc. (ADMS): $4.45; +10%.


Ovid Therapeutics Inc. (OVID): $2.39; -27%.

Iterum Therapeutics plc (ITRM): $5.08; -11%.

Mersana Therapeutics, Inc. (MRSN): $1.51; -11%.

Heron Therapeutics, Inc. (HRTX): $17.42; -10%.

Amicus Therapeutics, Inc. (FOLD): $7.85; -10%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

DBVT – DBV Technologies S.A.
Viaskin Peanut
Peanut allergy - ages 4 to 11 years

PDUFA PDUFA date August 5, 2020 (likely to be extended). Advisory Committee meeting slated for May 15, 2020 has been cancelled.
$471.9 million

HCM – Hutchison China MediTech Limited
Indolent Non-Hodgkin lymphoma (NHL)

Phase 1b Phase 1/1b trial initiation announced October 4, 2019.
$4.2 billion

SRPT – Sarepta Therapeutics Inc.
MYO-101 (SRP-9003)
Limb-girdle Muscular Dystrophy Type 2E (LGMD2E)

Phase 1/2 Phase 1/2 one-year functional results from the low dose cohort presented June 8, 2020. Three patients showed improvement in functional mobility of 4,6 and 7 points.
$13.3 billion